Amylin Receptor Research: A Receptor That Has to Be Assembled

Amylin receptors are built from a calcitonin receptor and an accessory protein. What that architecture means, and what the published research reports.

By Published Updated

Every other receptor described in this library is a protein encoded by a gene. Search a genome for the GLP-1 receptor and it is there, one gene, one product. Search for the amylin receptor and there is nothing to find.

That is not a gap in the annotation. Amylin receptors do not exist as separate gene products. They are assembled from two proteins that each have a different identity on their own, and the resulting complex has pharmacology that neither component has. This article sets out what that architecture is, what follows from it, and what the published research at each level reports. It describes research and contains no guidance of any kind on handling any material.

What an amylin receptor actually is

Amylin — also called islet amyloid polypeptide — is a 37-residue hormone secreted by pancreatic beta cells alongside insulin. Its receptors are formed when the calcitonin receptor, itself a class B1 G protein-coupled receptor, associates with one of a small family of single-transmembrane accessory proteins called receptor activity-modifying proteins.

The accessory proteins were described in 1998, in work showing that they regulate the transport and ligand specificity of the calcitonin-receptor-like receptor — that is, that an accessory protein can determine what a receptor is [2]. The following year, the same principle was applied to the calcitonin receptor itself: multiple amylin receptor phenotypes were shown to arise from the interaction of receptor activity-modifying proteins with the calcitonin receptor gene product [3]. That is the experiment that defines what an amylin receptor is.

The resulting complexes are conventionally designated AMY1, AMY2 and AMY3, after which accessory protein is involved. The reference pharmacology of the system — the complexes, their tissue distribution, their ligand preferences and their clinical relevance — was consolidated in a 2015 review that remains the standard account [6].

What follows from that architecture

Three consequences follow, and each of them changes how a statement about "amylin receptor agonism" should be read.

There is no single target to describe. There is a family of complexes whose relative abundance differs by tissue. "Amylin receptor agonism" therefore names a distribution of activities rather than one activity, and two compounds described the same way may be engaging different members of the family in different proportions [6].

Selectivity is a design problem, not a formality. Because the calcitonin receptor is the shared component, a molecule that engages amylin receptors also has a relationship to the calcitonin receptor itself, and selectivity between them is something that has to be engineered rather than assumed [3, 6].

Receptor subtype identification is genuinely difficult. Pharmacological characterisation of amylin receptors in native tissue — as opposed to in cells transfected with a chosen combination — has been attempted directly, and the published work frames the problem as one of identifying subtypes rather than of measuring a known one [5].

For comparison: the GLP-1 receptor was cloned from pancreatic beta cells in 1992 as a single gene product [1], and nothing in its pharmacology requires an accessory protein. The two systems are both class B1 in origin and are otherwise structurally unlike each other.

What the cell-based research established

In vitro research

The defining work at this receptor is cell-based, and it predates every compound now in development by two decades.

The accessory protein principle. Receptor activity-modifying proteins were shown in 1998 to regulate the transport and ligand specificity of the calcitonin-receptor-like receptor, establishing that a single receptor gene product can present more than one pharmacology depending on what it is co-expressed with [2].

Amylin receptors specifically. In 1999, multiple amylin receptor phenotypes were shown to arise from interaction of those proteins with the calcitonin receptor gene product [3]. This is the paper that makes amylin receptors a defined pharmacological object.

Native-tissue characterisation. Pharmacological characterisation of rat amylin receptors examined the problem of identifying subtypes outside a transfected system [5].

Compound-level characterisation is thinner than the receptor-level work. The published description of cagrilintide is a medicinal-chemistry account of the development of a stable, lipidated long-acting amylin analogue and the structure-activity work that selected it from its alternatives, rather than a receptor-profiling paper [8]. Quantitative potency figures for it at each amylin receptor subtype are not stated there and are not reproduced here. The discovery characterisation of eloralintide, described as a selective amylin receptor agonist, reports its profile alongside a first clinical proof of concept [13].

These are observations in transfected cells and native membrane preparations. They describe molecular pharmacology and establish nothing about animals or people.

What the human research reports

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

The earlier generation

Pramlintide, a short-acting amylin analogue, is the compound that established amylin receptor agonism as a clinical proposition. It was studied as an adjunct to insulin in type 1 diabetes and reported in randomised controlled trials, including a one-year randomised trial of glycaemic and weight control [4].

Long-acting analogues: cagrilintide

Phase 1b in combination. 96 participants aged 18–55 with a body-mass index of 27.0–39.9 kg/m², at a single centre; 95 exposed. Cagrilintide exposure was proportional to the amount administered and did not affect semaglutide exposure or elimination. Cagrilintide half-life was 159–195 hours with a median time to maximum concentration of 24–72 hours; semaglutide half-life in the same participants was 145–165 hours. Of 566 adverse events in 92 participants, 207 (37%) were gastrointestinal disorders, most mild to moderate [7, 16].

Phase 2 as a single agent. 906 adults without diabetes at 57 sites in ten countries, randomised across a range of administered amounts, with liraglutide 3.0 mg as an active comparator and placebo. Under the trial-product estimand, mean percentage reductions in body mass across the cagrilintide groups were 6.0% to 10.8% (6.4–11.5 kg) against 3.0% (3.3 kg) for placebo at week 26; at the highest amount, 10.8% against 9.0% for liraglutide, an estimated treatment difference of 1.8%, p = 0.03. Gastrointestinal events occurred in 41–63% against 32% on placebo, principally nausea at 20–47% against 18% [9, 17].

Phase 2 with a monotherapy arm for each component. 92 adults with type 2 diabetes randomised 1:1:1 to the combination with semaglutide, semaglutide alone, or cagrilintide alone, all escalated to 2.4 mg once weekly over 32 weeks. Mean glycated haemoglobin change was −2.2 percentage points for the combination, −1.8 for semaglutide alone and −0.9 for cagrilintide alone; the combination was superior to cagrilintide alone but not to semaglutide alone (p = 0.075). Mean change in body mass was −15.6%, −5.1% and −8.1% respectively [10]. With roughly thirty participants per arm this trial is informative about direction and much weaker about magnitude.

Phase 3 as a fixed combination. The REDEFINE trials tested the co-formulation of cagrilintide and semaglutide in adults with overweight or obesity and, separately, in adults who also had type 2 diabetes [12, 11, 19, 18]. These address what the combination adds; they are not trials of amylin receptor agonism alone.

Long-acting analogues: eloralintide

Eloralintide, described as a selective amylin receptor agonist, has reported a phase 1 proof of concept alongside its discovery characterisation [13] and a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial [14]. Its relevance to this article is that it is a selective agonist rather than a component of a combination, which makes it the compound most likely to produce evidence about amylin receptor agonism as such.

The class of long-acting amylin-related peptides has been reviewed as a group [15].

What the human record does not contain

No amylin analogue has reported a clinical-outcome trial — none counting deaths, myocardial infarctions, strokes or kidney failure. No trial has attributed an effect to a specific amylin receptor subtype, because no clinical tool distinguishes them. And no amylin receptor agonist other than pramlintide has an approval: cagrilintide and eloralintide are investigational, and neither is approved by the U.S. Food and Drug Administration for any indication.

Why amylin is studied alongside incretin pharmacology

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

Amylin receptor agonists are the one class in this part of the library that is usually developed in combination with something else rather than against it, and the reason is mechanical.

Because amylin receptors and the GLP-1 receptor are different proteins in different systems, a compound at one cannot compete with or cross-react at the other. Published pharmacokinetic work confirms the absence of interaction directly: co-administration did not affect semaglutide exposure or elimination, and each compound's half-life in the same participants was what it was alone [7].

That is a different kind of combination from a multi-agonist molecule. A tri-agonist engages three receptors with one chain and therefore has one pharmacokinetic profile; a co-formulation of two peptides has two, and the trials that test it have to establish both. The three-arm phase 2 trial described above is the clearest example of a design that separates the components [10], and it is unusual precisely because most combination trials do not include monotherapy arms.

What remains unsettled

Which receptor subtype matters. AMY1, AMY2 and AMY3 differ in tissue distribution and ligand preference [6, 3], and no clinical result has been attributed to any one of them.

What selectivity against the calcitonin receptor buys. Selectivity is a stated design objective for compounds in this class [13], and no trial has compared a more selective agonist with a less selective one.

Whether amylin receptor agonism has effects that translate to outcomes. Every published endpoint in this class is a surrogate — glycated haemoglobin, body mass, adverse-event rates. No outcome trial has reported.

All the clinical research described here studied pharmaceutical material, manufactured to a regulatory standard, administered under registered protocols in defined populations under clinical supervision. None of it is research into, or evidence about, research-grade material supplied for laboratory use.

Frequently Asked Questions

What is an amylin receptor?
Not a single gene product. Amylin receptors are complexes formed when the calcitonin receptor associates with one of the receptor activity-modifying proteins, and the resulting complexes have pharmacology that neither component has alone [2, 3]. They are conventionally designated AMY1, AMY2 and AMY3, after which accessory protein is involved [6].
How is that different from the GLP-1 receptor?
The GLP-1 receptor is one gene product, cloned from pancreatic beta cells in 1992, requiring no accessory protein [1]. An amylin receptor has to be assembled, exists in several forms, and its relative abundance differs by tissue — so amylin receptor agonism names a distribution of activities rather than one activity [6].
What is amylin?
A 37-residue hormone secreted by pancreatic beta cells alongside insulin, also called islet amyloid polypeptide. Its pharmacology, physiology and clinical relevance were consolidated in a 2015 reference review [6].
Which amylin receptor agonists have been studied clinically?
Pramlintide, a short-acting analogue studied as an adjunct to insulin in type 1 diabetes [4]; cagrilintide, a long-acting lipidated analogue with published phase 1b, phase 2 and phase 3 combination work [7, 9, 10, 12]; and eloralintide, a selective agonist with phase 1 and phase 2 results [13, 14]. The class has been reviewed as a group [15].
Why is cagrilintide usually studied with semaglutide?
Because the two engage separate receptors in separate systems, so there is a mechanistic rationale for combining them, and published pharmacokinetic work found no interaction — co-administration did not affect semaglutide exposure or elimination [7]. The phase 3 REDEFINE programme tests the fixed co-formulation [12, 11].
Is there evidence for cagrilintide on its own?
Some, and it is limited. A phase 2 trial in 906 adults compared a range of administered amounts against placebo and against liraglutide 3.0 mg, not against semaglutide [9]. A three-arm phase 2 trial in 92 adults with type 2 diabetes included a cagrilintide monotherapy arm alongside semaglutide monotherapy and the combination, with roughly thirty participants per arm [10].
Are any amylin receptor agonists approved?
Pramlintide is an approved product in the United States. Cagrilintide and eloralintide are investigational and are not approved by the U.S. Food and Drug Administration for any indication. No amylin analogue has reported a clinical-outcome trial.

References

  1. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1 Proceedings of the National Academy of Sciences of the United States of America; 1992. PMID 1326760 doi:10.1073/pnas.89.18.8641
  2. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor Nature; 1998. PMID 9620797 doi:10.1038/30666
  3. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product Molecular Pharmacology; 1999. PMID 10385705 doi:10.1124/mol.56.1.235
  4. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial Diabetic Medicine; 2004. PMID 15498087 doi:10.1111/j.1464-5491.2004.01319.x
  5. Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes British Journal of Pharmacology; 2012. PMID 22014233 doi:10.1111/j.1476-5381.2011.01717.x
  6. Amylin: Pharmacology, Physiology, and Clinical Potential Pharmacological Reviews; 2015. PMID 26071095 doi:10.1124/pr.115.010629
  7. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial The Lancet; 2021. PMID 33894838 doi:10.1016/S0140-6736(21)00845-X
  8. Development of Cagrilintide, a Long-Acting Amylin Analogue Journal of Medicinal Chemistry; 2021. PMID 34288673 doi:10.1021/acs.jmedchem.1c00565
  9. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial The Lancet; 2021. PMID 34798060 doi:10.1016/S0140-6736(21)01751-7
  10. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial The Lancet; 2023. PMID 37364590 doi:10.1016/S0140-6736(23)01163-7
  11. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes The New England Journal of Medicine; 2025. PMID 40544432 doi:10.1056/NEJMoa2502082
  12. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity The New England Journal of Medicine; 2025. PMID 40544433 doi:10.1056/NEJMoa2502081
  13. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept Molecular Metabolism; 2025. PMID 41109426 doi:10.1016/j.molmet.2025.102271
  14. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial The Lancet; 2025. PMID 41207310 doi:10.1016/S0140-6736(25)02155-5
  15. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes Peptides; 2026. PMID 41747885 doi:10.1016/j.peptides.2026.171480
  16. A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese. NCT03600480
  17. Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.. NCT03856047
  18. A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight. NCT05394519
  19. A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight. NCT05567796

Every identifier above is resolved against PubMed, Crossref or ClinicalTrials.gov at build time, and the title returned by the register is compared with the title stored here. A page does not publish if a reference fails to resolve.

Research-Use Information

For in vitro research use only. This material is a laboratory reagent. It is not a drug, food, dietary supplement, or cosmetic and is not for human or veterinary use, including ingestion, injection, or any other administration. No information on this page describes or implies any effect in humans or animals. Sold only to researchers under our Terms of Sale.